US OptionsDetailed Quotes
PTN241115C2500
- 0.05
- 0.000.00%
15min DelayTrading Oct 30 11:51 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume324 Open Interest2.50Strike Price0.00Turnover264.20%IV94.66%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1691Delta0.3656Gamma26.20Leverage Ratio-0.0061Theta0.0001Rho4.43Eff Leverage0.0007Vega
Palatin Technologies Stock Discussion
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
• Topline results expected in 1Q calendar year 2025
• Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight
• Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compoun...
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
• Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)
◦ Patient Dosing Commenced 3Q Calendar Year 2024
◦ Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024
◦ Topline Results Expected 1Q Calendar Year 2025
• Dry Eye...
3 MINUTES AGO, 7:30 AM EDT
VIA PR NEWSWIRE
Dry Eye Disease (DED): PL9643
◦ MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies
▪ FDA Confirms Protocols and Endpoints
▪ Targeting Enrollment Start in 4Q Calendar Year 2024
▪ Topline Results Anticipated 4Q Calendar Year 2025
◦ Potential Collaboration/Funding Discussions Ongoing
• Obesity: Phase 2 Clinical Study ...
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for Pl9643 in Dry Eye Disease (Ded)
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
Palatin Technologies (NYSE American: PTN) has received FDA confirmation for the protocols and endpoints of its remaining Phase 3 pivotal clinical trialsfor PL9643 in Dry Eye Disease (DED). The trials, MELODY-2 and MELODY-3, are set to begin patient enrollment in Q4 2024, with topline results expected by year-end 2025. If successful, an NDA submi...
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered With Tirzepatide (GLP-1) for the Treatment of Obesity
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Technologies (NYSE American: PTN) has initiated patient dosing in a Phase 2 clinical study of bremelanotide co-administered with tirzepatide for obesity treatment.
The study, BMT-801, aims to enroll up to 60 patients across four U.S. sites, with full enrollment expected in Q3 2024 and topline results in Q1 2025....
No comment yet